Publications by authors named "Gargi D Basu"

Claim this Profile
C
Comprehensive genomic profiling of over 10,000 advanced solid tumors.
Jean-Paul De La O, Jess R Hoag, Angela K Deem, Min Wang, Arthur Starodynov, Gargi D Basu

Oncotarget· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a Novel Fusion with Targeted Therapeutic Implications in Locally Advanced Pediatric Cholangiocarcinoma: A Case Report.
Sarah G Mitchell, Gargi D Basu, Bree Eaton, Laurie J Goodman, Kelly C Goldsmith

Case Rep Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.
Semir Vranic, Gargi D Basu, David W Hall, Zoran Gatalica

Acta Med Acad· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addendum: The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series.
Kevin Drenner, Gargi D Basu, Laurie J Goodman, Audrey A Ozols, Janine R LoBello

Oncotarget· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care.
Ryan J Summers, Sharon M Castellino, Christopher C Porter, Tobey J MacDonald, Gargi D Basu

JCO Precis Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial.
Patricia M LoRusso, Aleksandar Sekulic, Jeffrey A Sosman, Winnie S Liang, John Carpten, Gargi D Basu

PLoS One· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series.
Kevin Drenner, Gargi D Basu, Laurie J Goodman, Audrey A Ozols, Janine R LoBello

Oncotarget· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra.
Tracey White, Szabolcs Szelinger, Janine LoBello, Amy King, Jessica Aldrich, Gargi D Basu

Oncotarget· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.
Zoran Gatalica, Carrie Snyder, Todd Maney, Anatole Ghazalpour, Daniel A Holterman, Gargi D Basu

Cancer Epidemiol Biomarkers Prev· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases.
Zoran Gatalica, Sherri Z Millis, Semir Vranic, Ryan Bender, Gargi D Basu

Oncotarget· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells.
Shilpi Arora, Kristen M Bisanz, Lourdes A Peralta, Gargi D Basu, Ashish Choudhary

Gynecol Oncol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis.
Marc G Bingaman, Gargi D Basu, Tiana C Golding, Samuel K Chong, Andrew J Lassen

Anticancer Drugs· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation.
David O Azorsa, RiLee H Robeson, Danielle Frost, Bessie Meec hoovet, Gillian R Brautigam, Gargi D Basu

BMC Genomics· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.
David O Azorsa, Irma M Gonzales, Gargi D Basu, Ashish Choudhary, Shilpi Arora

J Transl Med· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.
Pinku Mukherjee, Gargi D Basu, Teresa L Tinder, Durai B Subramani, Judy M Bradley

J Immunol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma.
Teresa L Tinder, Durai B Subramani, Gargi D Basu, Judy M Bradley, Jorge Schettini

J Immunol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional evidence implicating S100P in prostate cancer progression.
Gargi D Basu, David O Azorsa, Jeffrey A Kiefer, Angela M Rojas, Sukru Tuzmen

Int J Cancer· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification.
Riina Kuuselo, Kimmo Savinainen, David O Azorsa, Gargi D Basu, Ritva Karhu

Cancer Res· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells.
Gargi D Basu, Winnie S Liang, Dietrich A Stephan, Lee T Wegener, Christopher R Conley

Breast Cancer Res· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO.
Gargi D Basu, Teresa L Tinder, Judy M Bradley, Tony Tu, Christine L Hattrup

J Immunol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
Gargi D Basu, Latha B Pathangey, Teresa L Tinder, Sandra J Gendler, Pinku Mukherjee

Breast Cancer Res· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model.
Pinku Mukherjee, Teresa L Tinder, Gargi D Basu, Latha B Pathangey, Lieping Chen

Breast Dis· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer.
Gargi D Basu, Latha B Pathangey, Teresa L Tinder, Michelle Lagioia, Sandra J Gendler

Mol Cancer Res· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer.
Barbara A Pockaj, Gargi D Basu, Latha B Pathangey, Richard J Gray, Jose L Hernandez

Ann Surg Oncol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis